Argentum Succeeds In Starting Patent Cancellation Trial Against Novartis AG' AFINITOR

Published: Oct 02, 2017

NEW YORK, Sept. 29, 2017 /PRNewswire/ -- The U.S. Patent & Trademark Office (PTO) on September 25, 2017 granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the last-expiring patent listed as covering Novartis Pharmaceuticals' AFINITOR® (everolimus tablet) drug in the Food & Drug Administration's Orange Book.  Argentum challenges claims 13 of Novartis' U.S. Patent No. 9,006,224, which the Orange Book states will expire in 2028.  The PTO concluded that Argentum has established a "reasonable likelihood that [Argentum] would prevail with respect to claims 13" of the patent.  The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board.  A final decision on patentability in the IPR is due within 1 year.

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.

View original content with multimedia:

SOURCE Argentum Pharmaceuticals

Back to news